<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high grade glioma cell lines derived from glioblastoma</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Roger</forename><surname>Gilabert-Oriol</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sebastian</forename><forename type="middle">G B</forename><surname>Furness</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Drug Discovery Biology Laboratory</orgName>
								<orgName type="institution">Monash Institute of Pharmaceutical Sciences</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Pharmacology</orgName>
								<orgName type="institution">Monash University (Parkville)</orgName>
								<address>
									<settlement>Victoria</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brett</forename><forename type="middle">W</forename><surname>Stringer</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">QIMR-Berghofer Medical Research Institute</orgName>
								<address>
									<settlement>Brisbane</settlement>
									<region>Queensland</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Weng</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Institut für Laboratoriumsmedizin</orgName>
								<orgName type="department" key="dep2">Klinische Chemie und Pathobiochemie</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Institute of Pharmacy</orgName>
								<address>
									<addrLine>Königin-Luise-Str. 2+4</addrLine>
									<postCode>14195</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hendrik</forename><surname>Fuchs</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Institut für Laboratoriumsmedizin</orgName>
								<orgName type="department" key="dep2">Klinische Chemie und Pathobiochemie</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bryan</forename><forename type="middle">W</forename><surname>Day</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">QIMR-Berghofer Medical Research Institute</orgName>
								<address>
									<settlement>Brisbane</settlement>
									<region>Queensland</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Angela</forename><surname>Kourakis</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><forename type="middle">W</forename><surname>Boyd</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">QIMR-Berghofer Medical Research Institute</orgName>
								<address>
									<settlement>Brisbane</settlement>
									<region>Queensland</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">L</forename><surname>Hare</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mayank</forename><surname>Thakur</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Institut für Laboratoriumsmedizin</orgName>
								<orgName type="department" key="dep2">Klinische Chemie und Pathobiochemie</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Terrance</forename><forename type="middle">G</forename><surname>Johns</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">Hudson Institute of Medical Research</orgName>
								<orgName type="institution" key="instit2">Monash University (Clayton)</orgName>
								<address>
									<settlement>Victoria</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Peter</forename><forename type="middle">J</forename><surname>Wookey</surname></persName>
							<email>pwookey@unimelb.edu.au</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Medicine (Austin Health</orgName>
								<orgName type="institution">University of Melbourne</orgName>
								<address>
									<settlement>Heidelberg), Victoria</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Department of Experimental Therapeutics</orgName>
								<orgName type="institution">BC Cancer Research Centre</orgName>
								<address>
									<addrLine>675 W 10 th Ave</addrLine>
									<postCode>V5Z IL3</postCode>
									<settlement>Vancouver</settlement>
									<region>BC</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Department of Medicine/Cardiology Lance Townsend Building</orgName>
								<orgName type="institution">University of Melbourne</orgName>
								<address>
									<addrLine>Level 10, Studley Road</addrLine>
									<postCode>3084</postCode>
									<settlement>Austin Campus, Austin Health, Heidelberg</settlement>
									<region>VIC</region>
									<country key="AU">AUSTRALIA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high grade glioma cell lines derived from glioblastoma</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">B9EE63870BD7F4FFDBEAE6E6AE8D869D</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:20+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Calcitonin receptor</term>
					<term>immunotoxins</term>
					<term>targeting</term>
					<term>high grade glioma cell lines</term>
					<term>glioblastoma</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We have reported that calcitonin receptor (CTR) is widely expressed in biopsies from the lethal brain tumour glioblastoma by malignant glioma and brain tumour initiating cells (glioma stem cells) using anti-human CTR antibodies.</s><s>A monoclonal antibody against an epitope within the extracellular domain of CTR was raised (mAb2C4), and chemically conjugated to either plant ribosome-inactivating proteins (RIPs) dianthin-30 or gelonin, or the drug monomethyl auristatin E (MMAE), and purified.</s><s>In the high grade glioma cell line (HGG, representing glioma stem cells) SB2b, in the presence of the triterpene glycoside SO1861, the EC 50 for mAb2C4:dianthin was 10.0 pM and for mAb2C4:MMAE (antibody drug conjugate [ADC]) 2.5 nM, 250-fold less potent.</s><s>With the cell line U87MG, in the presence of SO1861, the EC 50 for mAb2C4:dianthin was 20 pM, mAb2C4:gelonin, 20 pM, compared to the ADC (6.3 nM), which is &gt;300 less potent.</s><s>Several other HGG cell lines that express CTR were tested and the efficacies of mAb2C4:RIP (dianthin or gelonin) were similar.</s><s>Co-administration of the enhancer SO1861 purified from plants enhances lysosomal escape.</s><s>Enhancement with SO1861 increased potency of the immunotoxin (&gt;3 log values) compared to the ADC (1 log).</s><s>The uptake of antibody was demonstrated with the fluorescent conjugate mAb2C4:AlexaFluor 568 and the release of dianthin-30:AlexaFluor488 into the cytosol following addition of SO1861 supports our model.</s><s>These data demonstrate that the immunotoxins are highly potent and that CTR is an effective target expressed by a large proportion of HGG cell lines representative of glioma stem cells and isolated from individual patients.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Successful treatment of recalcitrant tumours remains one of the great challenges of cancer research.</s><s>One such recalcitrant tumour, glioblastoma (GBM), is a deadly brain tumour (grade 4 astrocytoma <ref type="bibr" target="#b0">[1]</ref>).</s><s>One of the underlying features of GBM is the invasive potential of brain tumour initiating cells (BTIC) <ref type="bibr" target="#b1">[2]</ref> which are regarded as clones of cells with stem-like properties (glioma stem cells) <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>.</s><s>These cells are considered to have the capacity to differentiate into a variety of cell types <ref type="bibr" target="#b4">[5]</ref> including endothelial cells and pericytes, which are essential for the maintenance and expansion of the solid tumour.</s></p><p><s>Thus it is considered that these stem-like cells provide the malignant basis of glioblastoma and hence represent potentially important targets for treatment.</s></p><p><s>Conventional chemo-and radio-therapies, cyto-reductive surgery and trialled treatment modalities including Avastin (anti-VEGF antibody) therapy, have had minimal impact on the mean survival after diagnosis, which remains low at just 14-17 months <ref type="bibr" target="#b5">[6]</ref>.</s></p><p><s>The deployment of antibody drug conjugates (ADC) to treat recalcitrant tumours is a relatively recent research strategy in which the number of lead ADCs entering clinical trials has increased rapidly <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>.</s><s>Successful treatment is partly dependent on the properties of the antibody and its target, for efficient delivery of the drug into the tumour cell, as well as the efficacy of the drug itself.</s><s>Recently, an ADC based on an anti-EGFRvlll antibody (ABT-806) conjugated to monomethyl auristatin F (MMAF) resulting in an ADC (ABT-414) has been demonstrated to be effective in 22% of GBM patients in a phase I study <ref type="bibr" target="#b9">[10]</ref>.</s></p><p><s>Immunotoxins made from antibodies conjugated with either bacterial or plant toxins have been investigated for many years and there are examples of the former that have reached clinical trials.</s><s>However, studies involving plant-based immunotoxins have been less frequent and the development of ADCs for clinical trials is more advanced.</s><s>However, recent advances in immunotoxin research are beginning to change this preference.</s><s>Firstly, plant toxins such as the ribosome-inactivating proteins (RIP) dianthin-30 <ref type="bibr" target="#b10">[11]</ref> and gelonin 6 <ref type="bibr" target="#b11">[12]</ref> (originally extracted from seeds) are now synthesised as functional recombinant proteins.</s><s>Secondly, when administered in combination with enhancers of lysosomal escape (non-toxic co-factors) such as the triterpene glycoside SO1861 <ref type="bibr" target="#b12">[13]</ref> there is a decrease by several orders of magnitude in the effective concentration (EC 50 ) for cytotoxicity.</s><s>This enhancer is a plant triterpene glycoside, purified from the plant Saponaria officinalis L. <ref type="bibr" target="#b12">[13]</ref>, with specific structural features that enhance the cytotoxicity of immunotoxins conjugated with RIPs.</s><s>SO1861 has a triterpenoidal skeleton of oleanane type and two sugar side chains (bisdesmosidic) attached to it at positions C-3 and C-28 <ref type="bibr" target="#b13">[14]</ref>.</s><s>Such enhancers interact at non-toxic concentrations with the immunotoxin within the endosomal or lysosomal compartment of the target cells <ref type="bibr" target="#b13">[14]</ref> and promote release into the cytosol <ref type="bibr" target="#b14">[15]</ref> where the toxin targets ribosomes.</s></p><p><s>Our understanding of the role of calcitonin receptor (CTR) in cell physiology has been evolving over the last 20 years with new knowledge of the mechanisms of agonist bias <ref type="bibr" target="#b15">[16]</ref> and an increasing appreciation of the broad range of tissues in specific physiological states, in which CTR is expressed.</s><s>For instance, CTR expression may be transitory in wound healing <ref type="bibr" target="#b16">[17]</ref> and in neurons of the gut around birth <ref type="bibr" target="#b18">[18]</ref>.</s><s>It is expressed by activated lymphocytes <ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b20">20]</ref> and during foetal development <ref type="bibr" target="#b21">[21]</ref><ref type="bibr" target="#b22">[22]</ref><ref type="bibr" target="#b23">[23]</ref>.</s><s>Recently, we have proposed that CTR is externalised during the pre-apoptotic cell stress response <ref type="bibr" target="#b24">[24]</ref>.</s></p><p><s>CTR is a target of interest because it is expressed by malignant tumor cells of the brain tumor glioblastoma <ref type="bibr" target="#b25">[25]</ref>.</s><s>Furthermore, CTR is also expressed in other malignancies including multiple myeloma <ref type="bibr" target="#b26">[26]</ref>, leukemia <ref type="bibr" target="#b16">[17]</ref>, lymphoma <ref type="bibr" target="#b27">[27]</ref>, bone tumors <ref type="bibr" target="#b28">[28,</ref><ref type="bibr" target="#b29">29]</ref>, breast <ref type="bibr" target="#b30">[30]</ref> and prostate cancers <ref type="bibr" target="#b31">[31,</ref><ref type="bibr" target="#b32">32]</ref>, and medullary thyroid cancers <ref type="bibr" target="#b33">[33]</ref>.</s><s>The function(s) of CTR in the contexts of these different cancers is largely unknown, however an anti-apoptotic or survival activity has been proposed together with metabolic reprogramming <ref type="bibr" target="#b27">[27]</ref>.</s></p><p><s>Important considerations in the design of immunotoxins for the treatment of cancers includes the sufficient expression of the target receptor on the surface of BTICs compared to other exposed tissues <ref type="bibr" target="#b34">[34]</ref> and internalisation of receptors with the immunotoxin attached.</s><s>High grade glioma (HGG) cell lines <ref type="bibr" target="#b35">[35]</ref> derived from GBM, represent BTICs and include the subtypes, pro-neural, neural, classical and mesenchymal, classified according to gene profiling.</s><s>Five HGG cell lines (BAH1, JK2, PB1, SB2b &amp; WK1 <ref type="bibr" target="#b36">[36]</ref>) out of the twelve originally tested (~40%) were shown to express human CTR (hCTR) on immunoblots and four of these plus two others from a separate source, were included in this study.</s><s>CTR-positive HGG cell lines represent each of the subtypes listed above.</s></p><p><s>These HGG cell lines, when injected intracranially into immuno-deficient mice, form GBMlike tumours <ref type="bibr" target="#b37">[37]</ref>.</s></p><p><s>In this study CTR is evaluated as a potential target expressed by HGG cell lines and as an uptake mechanism for internalisation of immunotoxins.</s><s>For comparison, the efficacies of two anti-CTR immunotoxins based on an anti-CTR antibody conjugated to the plant toxins dianthin-30 and gelonin, and an ADC with monomethyl auristatin E <ref type="bibr" target="#b38">[38]</ref>, are reported here with and without SO1861.</s><s>Monomethyl auristatin is included in this study as it is frequently incorporated into ADCs tested in clinical trials and reported in the literature <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref> due to its toxicity as an anti-microtubule agent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>High Grade Glioma cell lines</head><p><s>In total seven HGG cell lines out of 14 screened expressed detectible levels of calcitonin receptor as determined by immunoblot.</s><s>These include four (JK2 <ref type="bibr" target="#b39">[39]</ref>, PB1 <ref type="bibr" target="#b40">[40]</ref>,</s></p><p><s>SB2b <ref type="bibr" target="#b41">[41]</ref> &amp; WK1 <ref type="bibr" target="#b36">[36,</ref><ref type="bibr" target="#b41">41]</ref>) from the QIMR-Berghofer Medical Research Institute (Brisbane, Australia).</s><s>Two further cell lines GBM-4 and GBM-L2 <ref type="bibr" target="#b42">[42]</ref> were obtained from the Monash Institute of Medical Research (Professor TG Johns).</s><s>These lines were all grown on Matrigel (Corning, US)-coated plastic surfaces under serum-free conditions in StemPro® NSC SFM -Serum-Free Human Neural Stem Cell Culture Medium (Thermo Fisher Scientific, US) with EGF, FGF2, glutaMAX plus penicillin/streptomycin (Thermo Fisher Scientific) and cultured at 37°C in a 95% humidified air, 5% CO 2 atmosphere <ref type="bibr" target="#b37">[37]</ref>.</s></p><p><s>The cell line U87MG, described extensively in the literature and derived from glioblastoma, was also included to provide a reference point for other published studies.</s></p><p><s>U87MG was maintained in DMEM-F12/10% FBS plus penicillin/streptomycin (Thermo Fisher Scientific) grown at 37°C in an atmosphere of 5% CO 2 .</s><s>For efficacy studies in the 96-well format and growth in chamber slides for confocal analysis, U87MG cells were cultured on Matrigel under identical serum-free conditions used for HGG cell lines, in StemPro® NSC SFM.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ribosome-inactivating proteins (RIP) and the drug monomethyl auristatin E (MMAE)</head><p><s>The RIP dianthin-30 [His 6 ] was synthesised as a recombinant protein in E. coli and purified by affinity (nickel-nitrilotriacetic acid [NTA] agarose) chromatography <ref type="bibr" target="#b43">[43]</ref>.</s><s>rGelonin was a gift from Professor Michael G Rosenblum (MD Anderson Cancer Center, Texas) which was synthesised and purified from E. coli <ref type="bibr" target="#b44">[44]</ref>.</s><s>MMAE (OSu-Glu-VC-PAB-MMAE) was purchased from Concortis Biosystems Corp., (US).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The enhancer triterpene glycoside SO1861</head><p><s>The extraction and isolation of the enhancer SO1861 from plant roots of Saponaria officinalis L. Caryophyllacea has been described <ref type="bibr" target="#b12">[13]</ref>.</s><s>The chemical structure of SO1861 has been solved and will be published in detail elsewhere (Dr Alexander Weng, personal communication).</s><s>At 3 µg/mL used in the growth assays, SO1861 is slightly toxic resulting in 10% retardation of cell proliferation.</s><s>For U87MG cells the concentration used was 1 µg/mL.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antibodies</head><p><s>These studies involved the use of a mouse monoclonal anti-human CTR antibody (mAb 46/08-2C4-2-2-4 [IgG1]) directed against an extracellular epitope (Welcome Receptor Antibodies [WRA, Melbourne) <ref type="bibr" target="#b24">[24]</ref>.</s><s>MAb1H10 (IgG 2A ) was raised against a cytoplasmic epitope (mAb 31/01-1H10, WRA, Melbourne; also distributed as MCA 2191 by BioRad, UK).</s><s>These antibodies have been previously validated (in the supplementary materials linked to <ref type="bibr" target="#b24">[24]</ref>) and further data published elsewhere <ref type="bibr" target="#b25">[25]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conjugation of toxins to mAb2C4</head><p><s>Dianthin-30[His 6 ] or gelonin was conjugated to mAb2C4 using succinimidyl 3-(2pyridyldithio) propionate (SPDP, Thermo Fisher Scientific).</s><s>This cross-linking procedure introduced a covalent disulphide bridge between the toxins and the monoclonal antibody.</s></p><p><s>In the case of dianthin-30[His 6 ] and mAb2C4, both proteins (molar ratio 1:1) were modified by SPDP and the molar ratios that were considered for their chemical reaction were protein:cross-linker of 1:3, 1:6 and 1:12.</s><s>In the case of gelonin and mAb2C4, in a first attempt both proteins (molar ratio 1:1) were modified by SPDP at a molar ratio protein:cross-linker of 1:6.</s><s>In a second and third attempt, only mAb2C4 (molar ratio gelonin:mAb2C4 of 3:1) was modified by SPDP at a molar ratio of protein:cross-linker of 1:3 and 1:6.</s></p><p><s>In brief, proteins (dianthin-30[His 6 ], gelonin and mAb2C4) were equilibrated in PBS-EDTA buffer (20 mM sodium phosphate, 150 mM sodium chloride, 1 mM EDTA, 0.02% sodium azide, pH 7.5) using a 5 mL Zeba polyacrylamide de-salting columns (Thermo Fisher Scientific).</s><s>Proteins were modified by addition of SPDP (20 mM in DMSO) for 60 min at room temperature.</s><s>Proteins were desalted again using 5 mL Zeba de-salting columns and then SPDP-modified toxin was reduced with the addition of dithiothreitol (DTT, final concentration of 50 mM) for 30 min at room temperature.</s><s>DTT was removed using a Zeba de-salting column.</s><s>Monoclonal antibody and reduced toxins (or non-modified gelonin containing one available cysteine) were allowed to react for 18 h at room temperature.</s><s>The conjugates were stored at 4°C pending further purification.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Monomethyl auristatin E (MMAE) was conjugated to mAb2C4 via the cross-linker</head><p><s>OSu-Glu-VC-PAB as indicated by the manufacturer (Concortis Biosystems Corp, US).</s><s>The chemical reaction was performed with a molar ratio mAb2C4:OSu-Glu-VC-PAB-MMAE of 1:7.</s><s>The antibody was equilibrated in the conjugation buffer 1 (CB1, 50 mM potassium phosphate, 50 mM sodium chloride, 2 mM EDTA, pH 6.5) using a 5 mL Zeba de-salting column.</s><s>Antibody was modified by addition of OSu-Glu-VC-PAB-MMAE (10mM in DMA).</s></p><p><s>Further organic solvent was added up to 10% (v/v) DMA and cross-linking reaction run for 18 h at room temperature.</s><s>The reaction was stopped by exchanging the CB1 with the conjugation buffer 2 (CB2, 50 mM sodium succinate, pH 5.0) using a 5 mL Zeba de-salting column.</s><s>Antibody-drug conjugate was stored at 4°C pending further purification steps.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Purification of immunotoxins and the ADC</head><p><s>MAb2C4:dianthin-30 [His 6 ].</s><s>The first step in purification involved chromatography with a nickel-NTA agarose matrix (Life Technologies).</s></p><p><s>In brief, 20 mM imidazole in buffer (50 mM sodium phosphate, 300 mM sodium chloride [pH 8.0]) was added to the crude cross-linked reaction mix, mixed with nickel-NTA agarose (3 mL bed volume) and equilibrated with inversion at 25°C for 60 min.</s><s>The bound matrix was poured into a 10 mL column, with gravity feed and washed with 3 column volumes of binding buffer (as above).</s><s>The bound products were eluted with 250 mM imidazole in buffer.</s><s>The eluted proteins (mAb2C4:dianthin-30[His 6 ] and dianthin-30[His 6 ]) were dialysed against PBS overnight at 6°C.</s><s>The second step of purification was achieved with chromatography on a peptide affinity column (thiopropyl sepharose 6B, prepared by Mimotopes, Clayton, Australia) using the peptide sequence (CSGS-PSEKVTKYCDEKGVWFK, synthesised by Mimotopes) equivalent to the extracellular epitope of human CTR that binds mAb2C4.</s><s>This step excluded antibody products in which the binding determinants for the peptide sequence had been compromised during the conjugation step.</s><s>The dialysed material was passed down the affinity column, washed in 3 volumes of 20mM sodium phosphate (pH 7.0), eluted with 100 mM glycine (pH 2.2) and the fractions neutralised with 10% of the collected volume with 1 M TRIS (pH 9.0).</s><s>These fractions were dialysed overnight in PBS and concentrated using Amicon Ultra-15 centrifugal filters (10 kD cut off).</s><s>The yield of conjugated material after purification was approximately 8%, compared to the initial amounts of dianthin-30[His 6 ] and mAb2C4 used in the conjugation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MAb2C4:gelonin</head><p><s>The conjugated crude product mAb2C4:gelonin was purified in a twostep process, firstly with the affinity column described above.</s><s>The second chromatographic step was dependent on the binding of the product to HiTrap Blue HP matrix (GE Healthcare) <ref type="bibr" target="#b44">[44,</ref><ref type="bibr" target="#b45">45]</ref> and elution with sodium chloride.</s><s>The yield of the final product (mAb2C4:gelonin) was similar to that of mAb2C4:dianthin-30 [His 6 ].</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MAb2C4:MMAE</head><p><s>The conjugated crude solution of mAb2C4:MMAE was also purified by two chromatographic steps, firstly with the peptide affinity column described above.</s><s>This purification step eliminates inactive binding products of mAb2C4:MMAE that might have been generated during the conjugation as they pass through within the void volume.</s><s>The second step in purification was chromatography on a hydrophobic interactive matrix (HiTrap Phenyl HP, GE Healthcare) and the active fraction was eluted with a reverse ammonium chloride gradient.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Growth/cytotoxicity assays in the 96-well format</head><p><s>For efficacy studies in the 96-well format all cell lines were grown on Matrigel Total lactate dehydrogenase (LDH, lysed cells) and residual LDH (non-lysed samples)</s></p><p><s>were performed in triplicate.</s><s>LDH measured using an LDH cytotoxicity detection kit (Roche) and read on a FLUOstar OPTIMA (BMG Labtech).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Confocal microscopy of HGG cell lines and immuno-fluorescence with multichannel detection</head><p><s>The confocal analysis of the uptake of mAb2C4 into HGG cell lines was accomplished with mAb2C4 labelled with AlexaFluor 568 (AF568, Thermo Fisher Scientific) using conjugation of lysines with NHS succinimidyl esters of AF568 <ref type="bibr" target="#b24">[24]</ref>.</s></p><p><s>HGG cell lines were cultured (described above) to 50-80% confluence on 4-well glass slides (Lab Tek II chamber slides, NUNC) coated with Matrigel (Corning, US) in a humidified incubator (5% CO 2 ) at 37°C then washed with media without growth factors.</s></p><p><s>MAb2C4:AF568 (1 µg/mL) was added to 1 mL of fresh growth medium and the chamber slides incubated for 24 h in the incubator.</s></p><p><s>Cells were washed with PBS, fixed with 4% paraformaldehyde/PBS for 30 min and then washed twice with PBS.</s><s>Cells were blocked with 5% normal goat serum/1% bovine serum albumin for 1 h.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Slides</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>The principal aim of this study was to synthesize conjugates of mAb2C4 antibody including the immunotoxins mAb2C4:dianthin-30, mAb2C4:gelonin and the antibody:drug conjugate (ADC) mAb2C4:MMAE, for comparison of their efficacies to promote cell death in high grade glioma cell lines and U87MG.</s><s>The validation of mAb2C4, which binds to an extracellular linear epitope (epitope 4) of human CTR, has been presented elsewhere <ref type="bibr" target="#b24">[24]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expression of calcitonin receptor protein was determined by immunoblot</head><p><s>In Fig. <ref type="figure" target="#fig_5">1a</ref> is shown expression of CTR protein by HGG cell lines and the cell line U87MG, probed with the antibody mAb1H10 which recognises an intracellular epitope (band 'a').</s><s>In U87MG cells probed with mAb2C4 (band 'b') is shown the target of MW~55 kD.</s><s>Band 'c' is a product of degradation of CTR.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Syntheses and purification steps for immunotoxins and ADC</head><p><s>Chromatography with the peptide affinity column constructed with the peptide sequence used for immunization and the cloning/expression of mAb2C4, was used for purification of each conjugate (immunotoxin or ADC), and mAb2C4:AF568 (see Fig. <ref type="figure" target="#fig_4">3</ref>) as the bound material retains the capacity to bind to epitope 4 of CTR.</s><s>Any antibody with compromised binding capacity passes through in the flowthrough during chromatography.</s></p><p><s>In Fig. <ref type="figure" target="#fig_2">1</ref> b-e are images of SDS-PAGE gels which represent the stages of synthesis (Fig. <ref type="figure" target="#fig_2">1b</ref>, crude product, lane 1 and lane 2 [reduced] compared to mAb2C4 alone) and the purified mAb2C4:dianthin-30[His 6 ] (Fig. <ref type="figure" target="#fig_2">1c</ref>), following chromatography on nickel-NTA column and the peptide affinity column.</s><s>In Fig. <ref type="figure" target="#fig_2">1d</ref> is shown the profile of purified mAb2C4:gelonin following chromatography on the peptide affinity and HiTrap Blue HP columns, and in Fig. <ref type="figure" target="#fig_2">1e</ref>, purified mAb2C4:MMAE following chromatography on a peptide affinity column and HiTrap Phenyl HP.</s><s>Further details of the purifications of mAb2C4:dianthin, mAb2C4:gelonin and mAb2C4:MMAE can be found supplementary figures 1-3.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The comparative potency of immunotoxin versus ADC in HGG cell line SB2b and cell line U87MG</head><p><s>In Fig. <ref type="figure" target="#fig_5">2a</ref>  <ref type="table" target="#tab_1">1</ref>).</s></p><p><s>In the HGG cell line SB2b, SO1861 increased the potency of mAb2C4:dianthin-30 by 3 log values (from supplementary figure <ref type="figure">7</ref>) and mAb2C4:MMAE by 1 log value (Fig. <ref type="figure" target="#fig_3">2b</ref>).</s><s>With the HGG cell line JK2 treated with mAb2C4:dianthin and SO1861</s></p><p><s>(supplementary figure <ref type="figure">5</ref>) the EC 50 was 10.0 pM (Table <ref type="table" target="#tab_1">1</ref>), similar to the value calculated for SB2b.</s></p><p><s>We tested the biological activity of mAb2C4:dianthin-30 and mAb2C4:MMAE in the cell line U87MG as a reference cell line for comparison with other studies reported in the literature.</s><s>In the presence of SO1861 (Fig. <ref type="figure" target="#fig_3">2c</ref>) the EC 50 was 20.0 pM and 6.3 nM (Table <ref type="table" target="#tab_1">1</ref>) respectively, which is 300-fold less potent.</s><s>The EC 50 for mAb2C4:gelonin was similar to that for mAb2C4:dianthin-30, namely 20 pM (Table <ref type="table" target="#tab_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The potency of each immunotoxin vs ADC in a range of GBM cell lines</head><p><s>The EC 50 values in several high grade glioma cell lines are listed in supplementary</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The uptake of mAb2C4:AF568 into HGG cell lines and U87MG</head><p><s>In Fig. <ref type="figure" target="#fig_4">3</ref> is shown images of the uptake of mAb2C4:AF568 by cell lines JK2 (low [x20] magnification), and at higher [x63] magnification, SB2b, PB1 and U87MG.</s></p><p><s>Fluorescence associated with mAb2C4:AF568 is present on the cell membranes as well as concentrated in the perinuclear region.</s><s>Some of the latter fluorescence coincides with LAMP1 staining (green in Fig. <ref type="figure" target="#fig_5">3 d and f</ref>) as shown in yellow [overlap], although the extent of LAMP1-positivity varies considerably between the cell lines.</s><s>LAMP1 is commonly used to identify the late endosomal/lysosomal compartments.</s></p><p><s>Of note PB1, which is relatively resistant to mAb2C4:dianthin-30 showed uptake of mAb2C4:AF568 following live staining for one hour.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Triterpene glycoside SO1861 promotes the release of dianthin into the cytosol</head><p><s>The release of toxin with enhancer SO1861 from intracellular compartments was tested by pre-loading the U87MG cells with Alexa Fluor 488-labelled dianthin (dianthin:AF488) prior to real time imaging.</s><s>In Fig. <ref type="figure" target="#fig_5">4 a-d</ref>, U87MG cells were incubated with the nuclear stain Hoechst 33342 (Fig. <ref type="figure" target="#fig_5">4a</ref>), pHrodo™ Red Dextran (Fig. <ref type="figure">4b</ref>), which is a marker for endosomes and lysosomes, and dianthin:AF488 (Fig. <ref type="figure">4c</ref>; merged image Fig. <ref type="figure">4d</ref>).</s><s>Dianthin:AF488 was detected in intracellular vesicles (Fig. <ref type="figure">4c</ref>) and co-localisation with pHrodo™ Red Dextran was observed (white arrows), indicating that dianthin:AF488 was transported into endosomes/lysosomes.</s></p><p><s>In further real time experiments, SO1861 was added to the cells in order to investigate the SO1861 mediated intracellular release of dianthin:AF488 into the cytosol.</s><s>This is quantified in Fig. <ref type="figure">4e</ref>.</s><s>The complete video sequence can be found in the supplementary video.</s><s>The cytosolic fluorescence indicates the release of dianthin:AF488 from intracellular compartments, a process that is mediated by SO1861.</s><s>In Fig. <ref type="figure">4</ref> (f-i) are</s></p><p><s>shown images taken from the supplementary video 1: panel (f) at 36 s when 5 µg/mL SO1861 was added, panel (g) at 136 s (no change), panel (h) at 180 s when dainthin:AF488 was released into the cytosol of cell 1 and panel (i) at 500 s when dainthin:AF488 was released into the cytosol of cell 2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>CTR was found expressed in a high percentage of human biopsies of glioblastoma <ref type="bibr" target="#b25">[25]</ref> and as reported here, by approximately 50% of HGG cell lines that were available to us.</s><s>These cell lines are considered to represent glioma stem cells.</s><s>In view of their role in the rapid expansion of the tumour and the relative resistance glioma stem cells confer to conventional therapies, we chose to target CTR and compare the efficacies of antibody:conjugates representing two immunotoxins and an ADC.</s><s>Part of the reasoning was the current popularity of ADCs being tested in clinical trials and our own interest in the potency of enhancers to improve the efficacy of RIP-based immunotoxins.</s><s>Thus the question we addressed concerned the comparison of the efficacies of immunotoxins and a related ADC tested on HGG cell lines in vitro.</s></p><p><s>The opportunity for this study began with our identification of the expression of CTR in glioblastoma and the validation of the antibody mAb2C4 which specifically binds an extracellular epitope of hCTR <ref type="bibr" target="#b24">[24]</ref>.</s></p><p><s>The first step was the synthesis of immunotoxins from mAb2C4 and the RIPs, diathin-30 <ref type="bibr" target="#b43">[43]</ref> and gelonin <ref type="bibr" target="#b44">[44]</ref>, and the drug MMAE <ref type="bibr" target="#b38">[38]</ref> with a linker, together known as vedotin.</s></p><p><s>A range of protein (antibody or toxin) and cross-linker SPDP molar ratios were tested and the optimal 1:6 for both were conjugated and further purified as described.</s><s>One important step in purification for each synthesis employed chromatography using a peptide affinity column which selected moieties that were capable of specifically binding the target sequence of hCTR located in the extracellular N-terminal domain and excluded modified antibody conjugates that no longer retained affinity for CTR.</s></p><p><s>Following the purification steps we determined with statistical accuracy the efficacy of treatment with mAb2C4:dianthin compared to mAb2C4:MMAE which involved 96-well assays to determine nett LDH and these were repeated four times (data shown in Fig. <ref type="figure" target="#fig_5">2ac</ref>).</s><s>With the HGG cell line SB2b, in the presence of SO1861, the EC 50 for mAb2C4:dianthin is 10.0 pM and for mAb2C4:MMAE 2.5 nM, which is approximately 250fold less potent.</s><s>Similarly with the cell line U87MG, in the presence of SO1861, the EC 50 for mAb2C4:dianthin is 20.0 pM and for mAb2C4:MMAE 6.3 nM, which is approximately 300-fold less potent.</s></p><p><s>To further explore the underlying biological variation that might be expected between patients we pooled the data for all HGG cell lines tested (data not shown) and U87MG treated with either mAb2C4:dianthin or mAb2C4:gelonin (EC 50 for both, 8 pM), but excluded the data derived with the HGG cell line PB1, which was resistant to both the immunotoxins.</s><s>A comparison with the pooled for the ADC (EC 50 , 10 nM) demonstrated the immunotoxins were greater than 3 logs more potent.</s><s>These pooled data demonstrate a remarkably similar sensitivity to both immunotoxins in a range of HGG cell lines.</s><s>This observation adds weight to the claim that CTR is a potential target for the treatment of glioblastoma as a high proportion of lines that express CTR were sensitive to the immunotoxins and were isolated from individual biopsies.</s></p><p><s>MAb2C4:MMAE was consistently less potent, with EC 50 in the nM range for both SB2b and U87MG, which is 250-300 times less potent than mAb2C4:dianthin-30 and mAb2C4:gelonin in the presence of SO1861.</s><s>Controls with unconjugated antibody (in the higher nM range) showed little effect on cell death.</s><s>In the absence of SO1861 mAb2C4:MMAE is 10 fold less potent and mAb2C4:RIPs were relatively ineffective (1000 fold less potent) such that their potencies are similar at approximately 10-20 nM (Table <ref type="table" target="#tab_1">1</ref> and supplementary figure <ref type="figure">6</ref>).</s><s>These data demonstrate the enhancer SO1861 has a high degree of specificity for the RIP.</s><s>The EC 50 data for these cell lines with mAb2C4:RIPs as described above is consistent with data published recently for cetuximab:dianthin-30 (5.3 pM), panitumumab:dianthin-30 (1.5 pM) and trastuzumab:diathin-30 (23 pM) coadministered with SO1861 <ref type="bibr" target="#b43">[43]</ref>.</s></p><p><s>The HGG cell line PB1 was resistant to mAb2C4:RIPs although it expressed CTR as determined by immunoblot (Fig. <ref type="figure" target="#fig_5">1a</ref>) and accumulated mAb2C4:AF568 (Fig. <ref type="figure" target="#fig_4">3</ref>).</s><s>This demonstration of resistance by PB1 alone compared to other cell lines, supports a mechanism in which uptake of immunotoxin is receptor-mediated rather than some nonspecific mechanism of internalisation.</s><s>Possible explanations for resistance in this cell line include that CTR is not efficiently internalised to reach the lysosomal compartment or the immunotoxin is not cleaved in the lysosomal compartment or that the RIP is not released into the cytosol.</s><s>We note the significant difference in the intracellular distribution of mAb2C4:AF568 in PB1 compared with SB2b and U87MG.</s><s>The large concentration of antibody suggests stalling and localisation in a peri-nuclear structure, perhaps the microtubule organising centre, with little access to the lysosomal compartment.</s></p><p><s>Seck et al <ref type="bibr" target="#b47">[47]</ref> originally proposed that CTR is embedded in the endosomal membrane and that this structure is bound to the cytoskeleton through the intermediate filament filamin.</s><s>We have extended this idea <ref type="bibr" target="#b24">[24]</ref> in which carboxyl terminal arginines together with a PDZ docking site are identified in all species and are predicted to be important sites of binding to tubulin.</s><s>We proposed that the mechanism of uptake of mAb2C4 conjugates was driven by receptor-mediated endocytosis with endosomes trafficked along the microtubules driven by molecular motors as reviewed <ref type="bibr" target="#b48">[48]</ref>.</s><s>When immunotoxins are transported by these endosomes, which subsequently become transformed into lysosomes (at low pH), the enhancers induce the release of cleaved RIPs as illustrated in Fig. <ref type="figure">4</ref> and supplementary video 1.</s><s>During this release, the RIP does not breach the plasma membrane in significant amounts but remains concentrated within the cytosol, consistent with the actions of enhancers in the release of RIP into the cytosol.</s></p><p><s>The relatively recent description of the powerful additional effects of enhancers and prior inefficient escape of RIPs from intracellular compartments in their absence, might be a major reason why plant immunotoxins have not yet achieved acceptance for clinical studies.</s><s>With successful animal studies this situation is likely to change.</s></p><p><s>Recent unpublished studies in mice by our group have investigated the toxicity of mAb2C4:dianthin with SO1861.</s><s>The mice tolerate the highest serum concentration tested, namely 300 pM immunotoxin, with no apparent effects on health (unpublished results).</s></p><p><s>Given the EC 50 in vitro is approximately 10 pM this provides a potential therapeutic window.</s><s>From these observations of tolerance it seems that CTR-neural circuits, the expression in distal tubules, thyroid and elsewhere, may escape exposure to the immunotoxin.</s><s>Any depleted populations, perhaps osteoclasts, might be replenished from bone marrow progenitors.</s><s>These results are also consistent with the lack of significant penetration of the vasculature in which endothelial cells are CTR-negative and supports the view that uptake of this immunotoxin into cells is a receptor-mediated process.</s></p><p><s>As far as we are aware this is the first published study in which an anti-G proteincoupled receptor antibody has been employed to target cancer stem cells.</s><s>In view of the expression of CTR by a range of tumour types it seems likely that this technology could be included in strategies for the treatment of other cancers (or subtypes) including breast, bone, prostate cancers and others (see Introduction).</s><s>We ask the question, is there a link between expression of CTR in cancer stem cells and expression in the pre-apoptotic cell stress response as proposed elsewhere <ref type="bibr" target="#b24">[24]</ref>?</s><s>In other words do some cancer cells exist in a state equivalent to the pre-apoptotic cell stress response?</s></p><p><s>In clinical trials immunogenicity associated with RIPs has been overcome with T-cell epitope depletion, for instance in the case of de-bouganin <ref type="bibr" target="#b49">[49]</ref>.</s><s>When combined with improved potency afforded with triterpene glycosides this is likely to create a powerful and effective combinational therapy for recalcitrant tumours.</s></p><p><s>In summary we have demonstrated that an anti-CTR antibody conjugated to an RIP can be deployed to target glioma stem cells (HGG cell lines).</s><s>These cells form the basis for resistance to chemotherapy and expansion of the deadly tumour glioblastoma.</s><s>The immunotoxins studied here are 250-300 times more potent than an equivalent ADC in a range of HGG cell lines and suggests more potent, aggressive treatment regimens can be configured than are currently being investigated in clinical trials.</s><s>This improved efficacy may be important for the successful treatment of recalcitrant tumours such as GBM and such strategies should be investigated with clinical trials as the next step to improve patient outcomes.</s><s><ref type="table" target="#tab_1">1</ref>.</s></p><note type="other">Figure legends</note></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>(</head><label></label><figDesc><div><p><s>Corning, US) under serum-free conditions in StemPro® NSC SFM (Life Technologies/Thermo Fisher Scientific) with growth factors and seeded at 2,500 cells per well.</s><s>Two to three hours after plating the cells, additions such as SO1861 and immunotoxins (mAb 2C4:dianthin-30[His 6 ], mAb2C4:gelonin) or ADC (mAb2C4:MMAE) were made.</s><s>Control plates included mAb2C4 with SO1861 or immunotoxin without SO1861.</s><s>Cells were incubated at 37°C for 4 days (U87MG) or 6 days (HGG cell lines).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>of fixed cells were incubated overnight at 6°C with rabbit anti-LAMP1 antibody (Cell Signalling) that detects lysosomes.</s><s>The secondary antibody used was goat anti-rabbit AlexaFluor 488 (4µg/mL, Thermo Fisher Scientific).</s><s>The samples were then mounted using DAPI aqueous mount (Prolong Gold, Thermo Fisher Scientific) to visualise the nuclei and dried at RT for several days in the dark.</s><s>The samples were imaged by confocal microscopy (Objectives x20 and x63) on a Zeiss Imager Z1/LSM 510 Meta confocal laser scanning system using Zen software.</s><s>Images (LSM format) were captured in a single focal plane (optical sections of 0.7 µm nominal thickness) or using the Z-series feature where ~ 15 optical sections were compressed (devolution using LSM Image Browser, Zeiss) to create a single plane image (TIFF format) equivalent to approximately 10 µm tissue thickness.Live cell imagingU-87 MG (ATCC® HTB-14™) cells were seeded (2000/dish) in Ibidi µ-Dishes (35 mm, low, Martinsried, Germany) and cultured in 2 mL Dulbecco's MEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.</s><s>After 92 h, the medium was removed and 1 mL fresh culture medium was added.</s><s>Dianthin:AF488 (100nM) was added and cells were incubated over night for an incubation period of 18 h.</s><s>Dianthin was labelled beforehand with Alexa-Fluor 488 5-TFP ester (Life Technologies) as described previously<ref type="bibr" target="#b46">[46]</ref>.The live cell imaging marker pHrodo™ Red Dextran (final concentration 40 µg/ mL, Life Technologies) was added 6 h before the end of the incubation period.</s><s>pHrodo™ Red Dextran is a live cell imaging marker for acidic intracellular compartments such as lysosomes.</s><s>Hoechst 33342 (Life Technologies) was added 30 min before the end of the incubation period.</s><s>Cells were washed with PBS (3×), covered with 1 mL live cell imaging solution (Life Technologies), supplemented with 1% FBS and 20 mM D-glucose and analyzed using a LSM780 laser scanning microscope, Axio Observer Z1 with a Plan-Apochromat 63×/1.4</s><s>Oil Objective (Carl Zeiss, Jena, Germany).</s><s>Cells were maintained at 37°C throughout the experiment.</s><s>Cells were continuously monitored (supplementary video) and 36 s after the start of the analyses SO1861 was added at a final concentration of 5 µg/mL.</s><s>To determine the SO1861 induced endosomal escape of dianthin:AF488 into the cytosol, regions of interest were assigned for individual cells and the increase of intensity was determined offline using ZEN 2.3 lite software (Carl Zeiss).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2 (</head><label>2</label><figDesc><div><p><s>Figure 2</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>( a )</head><label>a</label><figDesc><div><p><s>Merged image following the uptake of mAb2C4:AF568 (red) by cell line JK2.</s><s>(b) Merged image following the uptake of mAb2C4:AF568 by the cell lines SB2b.</s><s>(c) Image of PB1 (red channel).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="35,58.20,63.80,481.95,592.10" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="36,58.20,63.80,481.95,145.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="38,58.20,63.80,481.95,388.65" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>table 1</head><label>1</label><figDesc><div><p><s>after one experimental determination.The values for mAb2C4:dianthin-30 in the presence of SO1861 are close to 10 pM for SB2b, JK2, GBM-4 and GBM-L2, approximately 50 pM for WK1, but PB1 is quite resistant to both mAb2C4:dianthin-30 and mAb2C4:gelonin (supplementary figures 6, 7 and supplementary table1).</s></p></div></figDesc><table /></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of Interest</head><note type="other">Dr</note><p><s>(f) t=36 s, 5 µg/mL SO1861 was added.</s></p><p><s>(g) t= 136 s, no change.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 1:</head><p><s>EC 50 values derived from Fig. <ref type="figure">2</ref> are listed with different cell lines using immunotoxins mAb2C4:dianthin-30[His 6 ], mAb2C4:gelonin, and the ADC mAb2C4:MMAE in the LDH release assay as described for Fig. <ref type="figure">2</ref>. Each determination represents data from n independent experiments.</s><s>Also included are data derived from supplementary figure <ref type="figure">4</ref>. ND = No curve could be determined from data over the tested range 1-100pM.</s><s>ND* the EC 50 could be estimated from supplementary figure <ref type="figure">6</ref></s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The 2007 WHO classification of tumours of the central nervous system</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Louis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ohgaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">D</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Cavenee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jouvet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Scheithauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kleihues</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="97" to="109" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma</title>
		<author>
			<persName><forename type="first">R</forename><surname>Galli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Binda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Orfanelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cipelletti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gritti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Vitis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fiocco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Foroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dimeco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vescovi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="7011" to="7021" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Stem cells, cancer, and cancer stem cells</title>
		<author>
			<persName><forename type="first">T</forename><surname>Reya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">L</forename><surname>Weissman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">414</biblScope>
			<biblScope unit="page" from="105" to="111" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Stem cells and brain cancer</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Fomchenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Holland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Cell Res</title>
		<imprint>
			<biblScope unit="volume">306</biblScope>
			<biblScope unit="page" from="323" to="329" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Angiogenesis in glioblastoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Marsden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="1561" to="1563" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Primary brain tumours in adults</title>
		<author>
			<persName><forename type="first">A</forename><surname>Behin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hoang-Xuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Carpentier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Delattre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="page" from="323" to="331" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Hamilton</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.biologicals.2015.05.006</idno>
	</analytic>
	<monogr>
		<title level="j">Biologicals</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="318" to="332" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">New developments for antibody-drug conjugatebased therapeutic approaches</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>De Goeij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Lambert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Immunol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="14" to="23" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Weaponized antibodies use new tricks to fight cancer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ledford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">540</biblScope>
			<biblScope unit="page" from="19" to="20" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Reardon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Lassman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Den Bent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kumthekar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Merrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fichtel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Sulman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Munasinghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mandich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Roberts-Rapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ansell</forename><forename type="middle">P</forename><surname>Holen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Gan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename></persName>
		</author>
		<idno type="DOI">10.1093/neuonc/now257</idno>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Crystallization and preliminary X-ray diffraction analysis of two ribosome-inactivating proteins: lychnin and dianthin 30</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fermani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Falini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ripamonti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bolognesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Polito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Stirpe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Crystallogr D Biol Crystallogr</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="1227" to="1229" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">X-ray structure of gelonin at 1.8 A resolution</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Hosur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Satyamurthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Misquith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Surolia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Kannan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Biol</title>
		<imprint>
			<biblScope unit="volume">250</biblScope>
			<biblScope unit="page" from="368" to="380" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma</title>
		<author>
			<persName><forename type="first">B</forename><surname>Von Mallinckrodt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thakur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gilabert-Oriol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Durkop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Brenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lukas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Beindorff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Melzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fuchs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Future Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="2161" to="2175" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: an evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Thakur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mergel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Von Mallinckrodt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gilabert-Oriol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Durkop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Melzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fuchs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="475" to="483" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Improved intracellular delivery of peptide-and lipid-nanoplexes by natural glycosides</title>
		<author>
			<persName><forename type="first">A</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Manunta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thakur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gilabert-Oriol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Tagalakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Eddaoudi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Munye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Vink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wiesner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Eichhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Melzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Hart</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jconrel.2015.03.007</idno>
	</analytic>
	<monogr>
		<title level="j">J Control Release</title>
		<imprint>
			<biblScope unit="volume">206</biblScope>
			<biblScope unit="page" from="75" to="90" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Ligand-Dependent Modulation of G Protein Conformation Alters Drug Efficacy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Furness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Nowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Halls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Wookey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dal</forename><surname>Maso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Christopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wootten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sexton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.cell.2016.09.021</idno>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="739" to="749" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">Calcitonin receptor (CTR) expression in embryonic, foetal and adult tissues: developmental and pathophysiological implications</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wookey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zulli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schwarer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Darby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Leung</surname></persName>
		</author>
		<editor>Hay D, Dickerson I</editor>
		<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="page">27</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">related peptide family; form, function and future perspectives</title>
		<imprint>
			<publisher>Springer</publisher>
			<biblScope unit="page" from="199" to="233" />
			<pubPlace>Netherlands</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Transient expression of the calcitonin receptor by enteric neurons of the embryonic and early post-natal mouse</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Wookey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Furness</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Tissue Res</title>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="page" from="311" to="317" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Calcitonin receptors on cultured human lymphocytes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Marx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Aurbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Gavin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Buell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">249</biblScope>
			<biblScope unit="page" from="6812" to="6816" />
			<date type="published" when="1974">1974</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Calcitonin receptors on circulating normal human lymphocytes</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Body</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Glibert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nejai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Langendonck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Borkowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="675" to="681" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Transgenic mice reveal novel sites of calcitonin receptor gene expression during development</title>
		<author>
			<persName><forename type="first">C</forename><surname>Jagger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chambers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pondel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">274</biblScope>
			<biblScope unit="page" from="124" to="129" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Calcitonin receptor isoforms expressed in the developing rat kidney</title>
		<author>
			<persName><forename type="first">C</forename><surname>Tikellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xuereb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Casley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Brasier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Wookey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kid Int</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="416" to="426" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Ontogeny of calcitonin receptor mRNA and protein in the developing central nervous system of the rat</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tolcos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tikellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wookey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Comp Neurol</title>
		<imprint>
			<biblScope unit="volume">456</biblScope>
			<biblScope unit="page" from="29" to="38" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">A novel ligand of calcitonin receptor reveals a potential new sensor that modulates programmed cell death</title>
		<author>
			<persName><forename type="first">Sgb</forename><surname>Furness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Hare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kourakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Turnley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Wookey</surname></persName>
		</author>
		<idno type="DOI">10.1038/cddiscovery.2016.62</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Discov</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">16062</biblScope>
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The expression of calcitonin receptor detected in malignant cells of the brain tumour glioblastoma multiforme and functional properties in the cell line A172</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Wookey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Mclean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Furness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kourakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Hare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Rosenfeld</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2559.2011.04146.x28</idno>
	</analytic>
	<monogr>
		<title level="j">Histopathology</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="895" to="910" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro</title>
		<author>
			<persName><forename type="first">F</forename><surname>Silvestris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cafforio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Matteo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quatraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dammacco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Res</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="611" to="623" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo</title>
		<author>
			<persName><forename type="first">A</forename><surname>Venkatanarayan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Raulji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Norton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chakravarti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Coarfa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Sandur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Ramirez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Kingsley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Sananikone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rajapakshe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Naff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Parker-Thornburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bankson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Gunaratne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Flores</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">517</biblScope>
			<biblScope unit="page" from="626" to="630" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Calcitonin receptors of human osteoclastoma</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Nicholson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Horton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Sexton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D'</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Moseley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kemp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Pringle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Horm Metab Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="585" to="589" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Gorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Rudolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Flannery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Morton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Weremowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Krane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Goldring</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="2680" to="2691" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gillespie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Pu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Findlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="812" to="815" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Calcitonin receptor mRNA expression in human prostate</title>
		<author>
			<persName><forename type="first">G</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Burzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Di Sant'agnese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schoen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Deftos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gershagen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cockett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="376" to="381" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muralidharan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Shah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1425" to="1437" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Calcitonin receptor mRNA is expressed in human medullary thyroid carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Frendo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Delage-Mourroux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pichaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pidoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Guliana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jullienne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thyroid</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="141" to="147" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Antibody therapy of cancer</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Old</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="278" to="287" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Verhaak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Hoadley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Purdom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Wilkerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Golub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Mesirov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Alexe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tamayo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Weir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Winckler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jakkula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Feiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Hodgson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Sarkaria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Spellman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Speed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Meyerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Getz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Genome Atlas Research</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="98" to="110" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>Cancer Cell</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Stringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Al-Ejeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Ensbey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Jamieson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">C</forename><surname>Bruce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Offenhauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Charmsaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Ellacott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Harding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Leveque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Inglis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Allan</forename><forename type="middle">S</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Lackmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Osborne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Khanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Lickliter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="238" to="248" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Pollard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yoshikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">D</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Danovi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stricker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bayani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Head</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Squire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dirks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Stem Cell</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="568" to="580" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Francisco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Cerveny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Mixan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Klussman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Chace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">X</forename><surname>Rejniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Deblanc</surname></persName>
		</author>
		<author>
			<persName><surname>Toki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Doronina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Siegall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Senter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Wahl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="1458" to="1465" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Differential response of patient-derived primary glioblastoma cells to environmental stiffness</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Grundy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Leon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Griffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Stringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Fabry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cooper-White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Neill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scientific Reps</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">23353</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tivnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Johns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Stringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tiwari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Teo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Mcdonald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1459" to="1465" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Hosein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Head</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cosgrove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sminia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuro-oncol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="263" to="271" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">The regulation of mitochondrial DNA copy number in glioblastoma cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dickinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Yeung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Donoghue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mckenzie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Johns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">St</forename><surname>John</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Differ</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1644" to="1653" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and coapplication of SO1861</title>
		<author>
			<persName><forename type="first">R</forename><surname>Gilabert-Oriol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Trautner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Weise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bhargava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Niesler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Wookey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fuchs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thakur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Pharmacol</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="247" to="255" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Rosenblum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Kohr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Beattie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Beattie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Marks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Toman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cheung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Interfer Cyto Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="547" to="555" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Purification of immunotoxins containing the ribosome-inactivating proteins gelonin and momordin using high performance liquid immunoaffinity chromatography compared with blue sepharose CL-6B affinity chromatography</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Cumber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Parnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Wawrzynczak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Methods</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="15" to="24" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Saponins modulate the intracellular trafficking of protein toxins</title>
		<author>
			<persName><forename type="first">A</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thakur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Von Mallinckrodt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Beceren-Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gilabert-Oriol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wiesner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Eichhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Böttger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Melzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fuch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jconrel.2012.10.002</idno>
	</analytic>
	<monogr>
		<title level="j">J Control Release</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="74" to="86" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling</title>
		<author>
			<persName><forename type="first">T</forename><surname>Seck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Horne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">278</biblScope>
			<biblScope unit="page" from="10408" to="10416" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Cargo transport: molecular motors navigate a complex cytoskeleton</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Warshaw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Op Cell Biol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="41" to="47" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cizeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Grenkow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Entwistle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Macdonald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunother</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="574" to="584" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main">t=180 s, high intensity green fluorescence is evident in cell 1, which indicates the SO1861 mediated intracellular release of dianthin:AF488 into the cytosol</title>
		<imprint/>
	</monogr>
	<note>At 500 s, the leakage of dianthin:AF488 into the supernatant was restricted by the plasma membrane and is approximately 25% over 5 minutes. green trace</note>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title level="m" type="main">t=504 s, high intensity green fluorescence is evident in cell 2, which indicates the SO1861 mediated intracellular release of dianthin:AF488 into the cytosol. The calibration bar in (a) represents 20 µm</title>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
